Neuroendocrine tumors are a complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body.

1. Neuroendocrine Tumors
(NET)
Market Insights, Epidemiology,
and Market Forecast- 2028

2. NEUROENDOCRINE TUMORS (NET)
2
CLASSIFICATION
NETs classified as:
Gastroenteropancreatic neuroendocrine
tumors, Pancreatic neuroendocrine
tumors, Gastrointestinal neuroendocrine
tumors, Carcinoid tumor, Functioning
and, Non-functioning neuroendocrine
tumors.
SYMPTOMS
NETs gradually tend to appear when the
tumor grows or hormones are secreted
by the tumor itself. Some of the NETs
symptoms are discomfort or pain the in
the rectum, heartburn or indigestion,
bowel obstruction, stomach ulcers, and
patches of red, itchy and painful skin.
NEUROENDOCRINE TUMORS
Neuroendocrine tumors are a complex
group of tumors that develop
predominantly in the digestive or
respiratory tracts, but can occur in many
areas of the body.
ORIGIN
These tumors arise from cells called
neuroendocrine cells. Like all cancers,
NETs develop when the specialized cells
undergo changes causing them to divide
uncontrollably and grow into an
abnormal tissue mass (tumor).
DelveInsight © 2019 | All rights reserved

3. 3
Neuroendocrine Tumors
total prevalent
population in 7 major
markets (7MM)* was
approximately 452,900
in 2017.
Total Prevalence
01
It was estimated
approximately 199,000
Neuroendocrine Tumors
prevalent cases were
there in the United
States in 2017.
Prevalence in US
02
Germany had the highest
NET prevalent population
with 49,600 cases while
Spain had the lowest NETs
prevalent population of
27,000 in 2017.
Prevalence in Europe
03
There were 35,000 patients
having localized tumor,
13,000 patients having
regional tumor and 18,000
cases with distant tumor in
the United States in 2017.
Tumor Cases
04
NEUROENDOCRINE TUMORS EPIDEMIOLOGY
{*7MM includes - USA, EU-5 (Germany, Spain, Italy, France and UK), Japan}
The European 5 countries
and the US accounted for
43% and 44% respectively
of the NET total prevalent
cases in the 7MM* in 2017.
Cases
05
DelveInsight © 2019 | All rights reserved

4. 4
Neuroendocrine tumors therapeutic market in seven
major markets was USD 3,570.0 million in 2017.
The United States accounts for the largest
Neuroendocrine tumors market size, in comparison to
EU5 (the United Kingdom, Germany, Italy, France, and
Spain) and Japan.
Among the EU5 countries, Germany had the highest
Neuroendocrine tumors market size with
approximately USD 330.0 million in 2017.
Spain had the lowest Neuroendocrine tumors market
size with approximately USD 180.0 million in 2017.
NEUROENDOCRINE TUMORS MARKET
DelveInsight © 2019 | All rights reserved

5. 5
51.7% 12.7% 9.3% 7.6%
NETs MARKET (%) DISTRIBUTION IN 2017
6.9% 6.7% 5.1%
UnitedStates
Japan
Germany
France
United
Kingdom
Italy
Spain
DelveInsight © 2019 | All rights reserved

6. 6
Drug- CRN01941
by Crinetics Pharmaceuticals
Drug- Sulfatinib
By Hutchison MediPharma
Drug- RRx-001
By EpicentRx
Drug- Entrectinib
By Ignyta
Drug- ATG-008
By Antengene
NETs MARKET SIZE BY THERAPIES
Neuroendocrine Tumors market
dynamics is anticipated to
change in the coming years
owing to the expected launch of
emerging therapies during the
forecasted period of 2019-2028.
The emerging therapies and
companies involved in
Neuroendocrine Tumors
treatment are-
DelveInsight © 2019 | All rights reserved

7. 7
DelveInsight © 2019 | All rights reserved
For complete information on
Neuroendocrine Tumors Market Insights, Epidemiology & Market Forecast-2028
please click the link below
CLICK HERE
OR
Write Us At
info@delveinsight.com
COMPLETE INFORMATION

8. 8
DelveInsight is a premier Business Consulting and
Market Research firm focused exclusively on the
life science segment. With a wide array of smart
end-to-end solutions, the firm helps the global
Pharmaceutical and Bio-Tech companies formulate
prudent business decisions for improving their
performances to stay ahead of the competitors.
DelveInsight © 2019 | All rights reserved
ABOUT DELVEINSIGHT
ABOUT
To provide “insights across the value chain” and
helping the organization to take a prudent
business decision through the use and analysis of
actionable market intelligence. The mission also is
to provide the most effective result and efficient
service with utmost client care for maintaining a
long-term relationship with them.
MISSION
To be the most trusted market research & business
consulting firm in the world; and to continue
enable the Pharma & Bio-Tech companies to
achieve their goals with the best strategic insight
and competitive solution. The vision also is
inclusive of becoming a one-stop solution provider
for the entire gamut of drug development process.
VISION

9. 9
DelveInsight © 2019 | All rights reserved
SERVICE OFFERINGS BY DELVEINSIGHT
FORECASTING1
2
3
4
PIPELINE
CONSULTING
MARKET
INTELLIGENCE
OPPORTUNITY
ASSESSMENT
5
6
7
8
REPORT STORE
COMPETITIVE
ANALYSIS
PHARMDELVE

10. 10
DelveInsight © 2019 | All rights reserved
CONTACT US
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

11. THANK YOU